Impact of Glimepiride and Metformin on the Biomarker miR-150-5p in Patients with Type 2 Diabetes and Left Ventricular Diastolic Dysfunction

Background: Type-2 diabetes mellitus (T2DM) is a significant contributor to cardiovascular risk, with diabetic individuals having double the mortality rate compared to those without diabetes. Among the various early subclinical cardiac problems in type 2 diabetes, left ventricular diastolic dysfunction (LVDD) is the most easily identifiable impairment. Nevertheless, only a limited number of biomarkers can accurately forecast this group's cardiovascular events. Levels of miR-150-5p are reduced in patients with type 2 diabetes mellitus (T2DM), regardless of whether they have cardiovascular disease. Our findings also demonstrate a decrease in miR-150-5p levels in these patients. Lower levels of miR-150-5p in the blood have been observed in nearly all forms of cardiovascular disease, and its potential to predict various clinical outcomes has been extensively studied in patients.
Objective: To assess the effect of glimepride (Glm) and Metformin on cardiac parameter miR-150-5p in patients with type 2 diabetes and diastolic dysfunction.
Patients and methods: In a cross-sectional study that included 60 patients with type 2 diabetes and diastolic dysfunction in an age range of 45 to 65, the patients were divided into two groups: group G1 (received standard treatment for T2DM with Metformin 1g2 max daily dose ) and group G2 (received standard treatment for T2DM with Metformin + Glimepiride 4mg daily).
Results: Treatment with glimepride significantly increased miR-150-5p expression in patients with type 2 diabetes mellitus (T2DM) and left ventricular diastolic dysfunction (LVDD), according to this study. The rise was more pronounced in patients who were given Glimepiride and standard medical treatment.
Conclusions: Glimepiride plays an important role in improving cardiac biomarkers like miR-150-5p. Glimepiride use in diabetic patients with the addition of Metformin to usual diabetes type 2 treatment may benefit patients with cardiac complications.